🚨 Exciting results from #ESMO26!

Phase III KRAScendo-1: Divarasib outperformed sotorasib/adagrasib in KRAS G12C-mutated NSCLC.

🔹 PFS: 9.8 vs 5.7 months
🔹 OS: 17.7 vs 12.0 months
🔹 ORR: 58% vs 32%

Better efficacy with fewer grade ≥3 treatment-related adverse events!

Could divarasib become the new standard of care? 👀
@OncoAlert @weoncologists @StephenVLiu @GlopesMd @OpenMedKate